As the benefits of GLP-1s become more mainstream topic of conversation, even for people who don’t need to lose a lot of weight, but may need metabolic support to help with cholesterol, A1C or low grade chronic inflammation, we see the same questions come up:
The discussion around going off, weight rebound and maintenance dosing is often oversimplified. Some say weight always returns when patients go off. Others imply long-term medication is the only option to maintain. The reality is more nuanced and depends largely on underlying metabolic drivers.
Understanding those drivers changes the entire conversation –
What the Clinical Data Shows:
One of the most referenced discontinuation studies to date is the SURMOUNT-4 trial, published in the New England Journal of Medicine in 2023.
In this study:
For example, someone starting at 200 pounds would lose roughly 42 pounds, reaching about 158 pounds. When they stopped the medication and switched to placebo, the patient would regain about 14% – landing at 186 lbs, only 14 lbs lighter than their starting weight.
This study evaluated abrupt discontinuation. It did not include structured tapering, microdosing strategies, or individualized long-term metabolic planning.
In the STEP-4 trial, the rebound was more significant, ¾ of participants saw rebound almost equivalent to what was lost, but the underlying thread of abrupt discontinuation was the same.
That said, we never recommend discontinuing “cold turkey” or abruptly.
GLP-1 medications actively influence appetite signaling, insulin sensitivity, and energy regulation while in use. After coming off the medication, those physiologic systems gradually recalibrate, and weight trajectory reflects the strength of underlying metabolic drivers. What happens when you go off depends heavily on what was driving the weight in the first place.
When evaluating transition off a GLP-1, our team implemented root cause guidance when we started our practice many years ago. These are meant to highlight from patient to patient their specific root driver of weight regulation and not only does this impact our long-term strategy for maintenance, but also how we customize dosing as they are in active loss. Without going into too much detail, broadly, these fall into two categories: internal (genetic, biological, etc) and external (situational).
Internal Drivers
Internal drivers are rooted in physiology and metabolic regulation. These are often more resistant to lifestyle modification alone.
Examples include:
In these cases, a GLP-1 journey is providing ongoing metabolic support that the body needs in order to not gain weight – even with perfect nutrition and workout habits in place. These medications influence insulin sensitivity, satiety pathways, and central appetite regulation. When that support is removed, those regulatory systems return toward baseline. Over 12–18 months, metabolic pressure builds – blood sugar swings, higher insulin spikes after meals, hunger and satiety gradually return to where they were previously – and with those things: weight can come back. These patterns reflect physiology adjusting.
Long-term planning in this group may involve maintenance dosing, microdosing strategies, hormone optimization, or more robust lifestyle infrastructure.
The toughest part about internal root causes and long-term goals is how we frame this. I liken this to needing glasses -- we don't, as a society, say "Don’t want to rely on glasses forever, see if your eyes can handle it." When people's vision improves with glasses, that doesn’t mean that those people or their eyes were "weak" or "lazy" or "didn't make good choices" — it just means they were correcting something that needed support. The metabolic support is the same; for some people, some of it will be outside of their control and there are flags that indicate that.
External Drivers
External drivers are primarily circumstantial rather than rooted in chronic metabolic resistance.
Examples include:
In these scenarios, weight gain often developed during a specific and defined life phase. It’s not a lifetime or even an era (ie: your late 30s) of struggle. Once that barrier resolves and structure is rebuilt, the underlying metabolic system may be more neutral. After discontinuation, appetite signaling typically returns toward baseline. For those with predominantly external drivers, this often feels manageable rather than dysregulated.
The Transition Window
This transition timeline of going off and what to look for can vary for everyone, however over time, trajectories tend to diverge based on dominant drivers.
Internal drivers may show:
External drivers more commonly demonstrate:
These differences reflect how underlying physiology interacts with the environment of no support of a GLP-1 over time.
How Long Should You Stay on a GLP-1?
There is no universal timeline.
The appropriate duration of a GLP-1 journey depends on if you need metabolic support and the underlying metabolic drivers, long-term health goals, cardiometabolic markers and cardiometabolic risk, environmental stability (ie: are you able to work out? Are you able to meal prep?), etc. For some individuals, a GLP-1 journey functions as a bridge through a specific life season. For others, it provides sustained metabolic regulation in the presence of chronic biologic resistance.The decision to taper should be intentional, not reactive.
Rather than asking how quickly medication can be stopped, a more useful question is: What level of ongoing metabolic support allows my body and my health to remain stable long term? Long-term success is whatever focuses on alignment between physiology, environment, and strategy. Think: how much support can you bridge on your own?
GLP-1 medications do not permanently reset metabolism. At TAC, we approach every GLP-1 journey with depth and intention, aligning transition strategy with long-term metabolic stability and benchmark success, not just with weight, but with overall markers of optimized health (blood work, etc).
